Close
Almac
Achema middle east

News

Clinical Trials Diversity Continues To Be Area To Watch For

Biopharma companies as well as policymakers know the significance of assessing medical and drug products across a broad range of racial and ethnic universes so as to fully comprehend the medical effects on patients. This has indeed pushed the...

HPAPI Worldwide Market Is Booming – To Stay Today, Forever

As per a market report by Reportlinker, the worldwide highly potent active pharmaceutical ingredient- HPAPI sector is anticipated to breach the $34.04 billion mark by 2026 at a CAGR of around 8.5%. HPAPIs are substances that cause a biological response...

What To Do If A Loved One Is Abusing Prescription Drugs?

Abusing prescription drugs means taking medications recommended by a doctor or other healthcare provider, not as the professional intended. Establishing if a loved one is misusing prescription drugs can be challenging. This is because they’re legal, and you might...

Gene Therapy Trials – A Word of Advice From FDA Officials

Representatives from the US FDA Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies have said that the gene therapy clinical trials depend on the nature of the disease being treated and that the diseases that...

Cancer Vaccine Redesign – A Transformation In The Making

Researchers at Northwestern University's International Institute for Nanotechnology (IIN) have devised a novel method for dramatically increasing the potency of practically any vaccine. The researchers used chemistry and nanotechnology to alter the structural placement of adjuvants and antigens on...

RMAT Status Given To Cardiac Gene Therapy – A First From FDA

The Regenerative Medicine Advanced Therapies designation of RP-A501, which happens to be an adeno-associated virus-based gene therapy when it comes to the treatment of Danon disease, has been granted by the US Food and Drug Administration. According to Dr. Gaurav...

4 Factors That Pharma Supply Chains Need To Address Swiftly

The post-pandemic future of healthcare has compelled one to re-evaluate the supply chain from end-to-end. Be it new technologies, shortened clinical trials, next-gen medical innovations, digitization, or risk management, all have and are going to set new benchmarks and redefine...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »